Zhongshan Laibo Ruichen Biomedicine Co., Ltd.

Rabpharma's RAB001 Secures Additional IND Clearance, Expanding into Osteoarthritis

Patient enrollment has been completed for the RAB001 Phase II clinical trial!

Rabpharma Successfully Closes Oversubscribed Series A++ Funding Round to Accelerate R&D Progress

Early-Stage Osteonecrosis Phase II Clinical Trial Patient Recruitment

The Fifth Meeting of the First Session of the Board of Directors & 2024 Annual Shareholders' Meeting of Rabpharma Successfully Concluded